More than 11,000 bottles of a popular blood pressure pill are being pulled from pharmacy shelves across the country after routine lab checks found the tablets were not dissolving the way they are supposed to. The 25 mg chlorthalidone tablets were manufactured by India-based Inventia Healthcare and distributed in the United States by Rising Pharma Holdings of East Brunswick, New Jersey. The voluntary recall began June 5, 2026, and targets two lots that carry an April 2027 expiration date.
What Was Recalled
According to the Food and Drug Administration, the recall covers lot RISA24001 (100-count bottles) and lot RISB24002 (1,000-count bottles), for a total of 11,460 bottles. The agency lists the problem as "failed dissolution specifications," meaning sampled tablets did not dissolve according to the product's approved standards. The product was distributed nationwide and, at the time the entry was posted, the recall had not yet received a formal FDA classification.
Why "Failed Dissolution" Matters
Dissolution testing checks how quickly and completely a tablet releases its active ingredient. If a pill fails those tests, regulators worry that patients may not get the dose their doctor intended. Industry coverage, including Pharmaceutical Technology, notes that out-of-spec dissolution has triggered past recalls because slower or incomplete dissolution can cut effectiveness or make dosing unpredictable. In this case, the recall is tied to how the product performed in the lab, not to any allegation of contamination.
How To Tell If Your Bottle Is Affected
Look at your prescription bottle for lot numbers RISA24001 or RISB24002 and for NDC codes 64980-599-01 (100-count) or 64980-599-10 (1,000-count). The label lists Inventia as the manufacturer and Rising Pharma Holdings as the distributor. As reported by Fox San Antonio, the recalled bottles carry an April 2027 expiration date.
If your prescription matches those identifiers, talk with your pharmacist or prescriber before you change anything. Do not suddenly stop a blood pressure medication on your own. For official product and labeling details, see DailyMed and the U.S. contact information on Rising Pharma Holdings.
What Comes Next
The FDA sometimes posts enforcement records before issuing a consumer-facing press release, so the notice may be updated if the recall is reclassified or expanded. Consumers can watch for changes on the agency's recall pages. Industry watchers point out that this action lands in the middle of several hypertension drug recalls this spring, a run that has highlighted tighter scrutiny of imported generics.
If you notice unexpected symptoms after taking the medicine, contact your health care provider and file a report with FDA MedWatch. Questions about distribution or returning product can be directed to Rising Pharma Holdings.
